NCT05266300View on ClinicalTrials.gov

Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

CompletedOBSERVATIONAL
Enrollment

722

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 1, 2022

Study Completion Date

October 1, 2022

Conditions
Adverse Drug EventColon CancerBreast CancerPancreas CancerRectal CancerGastric CancerOesophageal CancerBile Duct Cancer
Interventions
GENETIC

DPYD genotype

"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)"

Trial Locations (1)

5000

The Department of Oncology at University of southern denmark, Odense

All Listed Sponsors
collaborator

Odense University Hospital

OTHER

lead

University of Southern Denmark

OTHER

NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. | Biotech Hunter | Biotech Hunter